Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 194

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 194
---
 50 mg cohort achieved a five-point decrease (p=0.0009) and the 75 mg cohort achieved a 4.7-point decrease (p=0.0022) in PANSS total score. Despite the highest dose cohort being exploratory and not sized to detect a statistically significant difference, the 100 mg cohort demonstrated a 6.8-point decrease (nominal p=0.0017) in PANSS total score when adjusted for placebo, which did achieve statistical significance.

136

Least square (LS) mean change from baseline in PANSS total score

The decrease in PANSS total score was observed as early as Day 8 with improvement seen through Week 4 across all three dose cohorts.

Change in PANSS total score from baseline over time.

At Week 4, the 50 mg, 75 mg, and 100 mg groups showed effect sizes of 0.61, 0.41, and 0.83, respectively, as highlighted in the table below.
Effect size is calculated by taking the difference in average PANSS change between two groups (an active treatment arm and placebo) and dividing it by a single measure of variability that combines both groups’ spreads—also called the
pooled standard deviation. The pooled standard deviation averages how much individual patients’ score changes scatter around their group’s mean. Clinicians value effect size because it conveys not just how large the average PANSS
improvement is, but also how consistently patients respond. Even if two treatments reduce PANSS by the same amount on average, the one with less scatter (i.e., a lower pooled standard deviation) will have a higher effect size—and gives a
clinician more confidence that a higher proportion of patients will see that same benefit.

137

| Dose of LB-102 |     | Effect Size versus Placebo |      |
| 50 mg          |     |                            | 0.61 |
| 75 mg          |     |                            | 0.41 |
| 100 mg         |     |                            | 0.83 |

Effect Size versus Placebo in our Phase 2 trial. Secondary Endpoints Within this trial, responders were defined as those who had a 20% or greater reduction in PANSS score at Week 4 (floor-adjusted). The three dose cohorts achieved a responder rate of 31.9% (p=0.0587), 32.1% (p=0.0160), and 43.5% (